Clinical Trial

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Recruiting
View on ClinicalTrials.gov →
Summary
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-07; most recent amendment 2026-04-15.
Trial Details
NCT Number NCT07123038
Lead Sponsor Sonoma Biotherapeutics, Inc.
Conditions Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Enrollment 36 participants
Start Date 2025-07-22
Primary Completion 2040-12 (estimated)
Study Completion 2040-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-16